FDA Committee Recommends Hospira’s Epogen/Procrit Biosimilar for Approval

An FDA advisory committee endorsed Hospira’s biosimilar version of Epogen and Procrit, used to stimulate the production of red blood cells.
Source: Drug Industry Daily